<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109315</article-id><article-id pub-id-type="publisher-id">ACM-37767</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_16313454.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  健康管理网络平台对心肌梗死后心力衰竭患者的干预研究
  Intervention Study of Health Management Network Platform in Patients with Heart Failure after Myocardial Infarction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>臧</surname><given-names>守亚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>艳伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>驰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>宝丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>甲亮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>喆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>长勇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院急诊内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2102</fpage><lpage>2107</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探究健康管理网络平台对心肌梗死后心力衰竭患者预后的干预研究，旨在改善心力衰竭患者的生存质量。方法：纳入青岛大学附属医院急诊内科2018年12月至2019年12月份收治的急性心肌梗死并发心力衰竭的214名患者作为研究对象，按照随机数表法，将其分为对照组(n = 107)和研究组(n = 107)；对照组为常规治疗后门诊随访，研究组为在常规治疗基础上通过健康管理网络平台加强患者用药指导及健康教育指导。比较2组患者在干预前后血浆中NT-pro BNP、6分钟步行距离(6MWD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)及患者再住院率。结果：对比两组患者干预前的血浆NT-pro BNP、6分钟步行距离(6MWD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)，差异无统计学意义(P &gt; 0.05)。干预治疗后研究组各项指标均显著优于对照组，差异具有统计学意义(P &lt; 0.05)。研究组再住院率低于对照组，但无显著性差异(P &gt; 0.05)。结论：通过健康管理网络平台对出院患者的干预指导，能够改善患者的心功能，提高患者生活质量，改善预后，降低患者再住院率。
    Objective: To explore the intervention of health management network platform on the prognosis of patients with heart failure after myocardial infarction in order to improve the quality of life of patients with heart failure. Methods: 214 patients with acute myocardial infarction complicated with heart failure admitted to the Emergency Department of The Affiliated Hospital of Qingdao University from December 2018 to December 2019 were enrolled as study subjects, and were divided into control group (n = 107) and study group (n = 107) according to the random number table method. The control group received outpatient follow-up after routine treatment, and the study group strengthened medication guidance and health education guidance for patients through the health management network platform on the basis of routine treatment. Plasma NT-proBNP, 6-minute walking distance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and patient rehospitalization rates were compared between the two groups before and after intervention. Results: after 12 months of intervention, plasma NT-proBNP, 6-minute walking distance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) were compared between the two groups before intervention, showing no statistically significant differences (P &gt; 0.05). After intervention treatment, all indexes of the study group were significantly better than those of the control group, and the difference was statistically significant (P &lt; 0.05). The rehospitalization rate of the study group was lower than that of the control group, but there was no significant difference (P &gt; 0.05). Conclusion: The intervention and guidance of the health management network platform for discharged patients can improve the cardiac function, improve the quality of life, improve the prognosis and reduce the rehospitalization rate of patients. 
  
 
</p></abstract><kwd-group><kwd>健康管理网络平台，心肌梗死，心力衰竭，健康指导，心功能, Health Management Network Platform</kwd><kwd> Myocardial Infarction</kwd><kwd> Heart Failure</kwd><kwd> Health Guidance</kwd><kwd> Cardiac Function</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探究健康管理网络平台对心肌梗死后心力衰竭患者预后的干预研究，旨在改善心力衰竭患者的生存质量。方法：纳入青岛大学附属医院急诊内科2018年12月至2019年12月份收治的急性心肌梗死并发心力衰竭的214名患者作为研究对象，按照随机数表法，将其分为对照组(n = 107)和研究组(n = 107)；对照组为常规治疗后门诊随访，研究组为在常规治疗基础上通过健康管理网络平台加强患者用药指导及健康教育指导。比较2组患者在干预前后血浆中NT-pro BNP、6分钟步行距离(6MWD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)及患者再住院率。结果：对比两组患者干预前的血浆NT-pro BNP、6分钟步行距离(6MWD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)，差异无统计学意义(P &gt; 0.05)。干预治疗后研究组各项指标均显著优于对照组，差异具有统计学意义(P &lt; 0.05)。研究组再住院率低于对照组，但无显著性差异(P &gt; 0.05)。结论：通过健康管理网络平台对出院患者的干预指导，能够改善患者的心功能，提高患者生活质量，改善预后，降低患者再住院率。</p></sec><sec id="s2"><title>关键词</title><p>健康管理网络平台，心肌梗死，心力衰竭，健康指导，心功能</p></sec><sec id="s3"><title>Intervention Study of Health Management Network Platform in Patients with Heart Failure after Myocardial Infarction</title><p>Shouya Zang<sup>1</sup>, Yanwei Liu<sup>1</sup>, Chi Zhang<sup>1</sup>, Baoli Xu<sup>1</sup>, Zhe Su<sup>2</sup>, Jialiang Guan<sup>2</sup>, Ze Li<sup>1</sup>, Changyong Zhou<sup>2*</sup></p><p><sup>1</sup>Qingdao University Medical College, Qingdao Shandong</p><p><sup>2</sup>Emergency Medical, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/35-1571577x5_hanspub.png" /></p><p>Received: Sep. 1<sup>st</sup>, 2020; accepted: Sep. 16<sup>th</sup>, 2020; published: Sep. 23<sup>rd</sup>, 2020</p><p><img src="//html.hanspub.org/file/35-1571577x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the intervention of health management network platform on the prognosis of patients with heart failure after myocardial infarction in order to improve the quality of life of patients with heart failure. Methods: 214 patients with acute myocardial infarction complicated with heart failure admitted to the Emergency Department of The Affiliated Hospital of Qingdao University from December 2018 to December 2019 were enrolled as study subjects, and were divided into control group (n = 107) and study group (n = 107) according to the random number table method. The control group received outpatient follow-up after routine treatment, and the study group strengthened medication guidance and health education guidance for patients through the health management network platform on the basis of routine treatment. Plasma NT-proBNP, 6-minute walking distance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and patient rehospitalization rates were compared between the two groups before and after intervention. Results: after 12 months of intervention, plasma NT-proBNP, 6-minute walking distance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) were compared between the two groups before intervention, showing no statistically significant differences (P &gt; 0.05). After intervention treatment, all indexes of the study group were significantly better than those of the control group, and the difference was statistically significant (P &lt; 0.05). The rehospitalization rate of the study group was lower than that of the control group, but there was no significant difference (P &gt; 0.05). Conclusion: The intervention and guidance of the health management network platform for discharged patients can improve the cardiac function, improve the quality of life, improve the prognosis and reduce the rehospitalization rate of patients.</p><p>Keywords:Health Management Network Platform, Myocardial Infarction, Heart Failure, Health Guidance, Cardiac Function</p><disp-formula id="hanspub.37767-formula36"><graphic xlink:href="//html.hanspub.org/file/35-1571577x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/35-1571577x8_hanspub.png" /> <img src="//html.hanspub.org/file/35-1571577x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>心肌梗死是因各种因素所致冠状动脉血管急性闭塞，血流中断，导致冠状动脉血液循环受阻，造成心肌缺血、缺氧等，导致心肌细胞凋亡、坏死，临床上以左心室心肌梗死最为常见 [<xref ref-type="bibr" rid="hanspub.37767-ref1">1</xref>]。缺血的心肌细胞会释放大量炎症因子，促进心室重构，造成心脏肥大，与此同时，释放的炎症介质可激活交感神经系统，使其过度兴奋，加重心肌缺血，造成心脏射血能力受损，心排血量不能满足机体组织代谢需要，最终造成心力衰竭的发生 [<xref ref-type="bibr" rid="hanspub.37767-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37767-ref3">3</xref>]，临床表现为呼吸困难、体力活动受限、体液潴留等主要症状。随着生活水平的提高及人口老龄化加剧，心力衰竭成为影响我国老年患者生命健康的主要因素之一 [<xref ref-type="bibr" rid="hanspub.37767-ref4">4</xref>]，据不完全统计，目前我国慢性心力衰竭患病率估计已达1.3%左右，现症患者约1000万，中国已经成为拥有最大心衰病患群体的国家 [<xref ref-type="bibr" rid="hanspub.37767-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.37767-ref6">6</xref>]。目前对于心力衰竭，尤其是心梗后心衰的防治现状不容乐观。急性心肌梗死的发病率在迅速增长，但心梗后心衰患病率并没有显著下降 [<xref ref-type="bibr" rid="hanspub.37767-ref7">7</xref>]，反而有增长的趋势。所以将对心梗后心衰患者管理与健康网络管理平台适宜结合，进而为病人提供优质的医疗资源及全面的健康管理措施。旨在降低心梗后心衰患者的再住院率，提高患者生活质量，改善预后。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>纳入青岛大学附属医院急诊内科2018年12月至2019年12月份收治的急性心肌梗死并发心力衰竭的214名患者作为研究对象，按照随机数表法，将其分为对照组和研究组各107例，对照组中男50例，女性57例，年龄为50~78岁，平均(64.5 &#177; 7.1)岁；高血压患者46例，糖尿病患者38例，血脂异常患者27例，吸烟史32例。研究组中，男性55例，女性52例，年龄为50~77岁，平均(64.7 &#177; 7.2)岁；高血压患者45例，糖尿病患者39例，血脂异常患者26例，吸烟史33例。两组患者一般资料比较差异无统计学意义(P &gt; 0.05)，具有可比性。</p></sec><sec id="s6_2"><title>2.2. 入选及排除标准</title><p>入选标准：① 符合心肌梗死的诊断标准 [<xref ref-type="bibr" rid="hanspub.37767-ref8">8</xref>]，且均经过冠状动脉造影检查确诊；② 符合心力衰竭的诊断标准 [<xref ref-type="bibr" rid="hanspub.37767-ref9">9</xref>]；③ 确诊为心肌梗死后心力衰竭患者；④ 病人已签署知情同意书。</p><p>排除标准：① 严重心律失常；② 并发严重肝脏、肾脏及肺脏功能不全者；③ 心力衰竭急性发作者；④ 严重精神疾病者；⑤ 恶性肿瘤者。</p></sec><sec id="s6_3"><title>2.3. 方法</title><p>对照组患者出院后行常规治疗及自我管理，病人出院后常规门诊随访。研究组是在此基础上实行基于网络平台的健康管理，建设网页平台，收录患者个人档案、检验检查数据、结果异常提醒、目标值设定等方面，通过电话或微信方式进行患者健康随访及出院用药指导，定期敦促患者门诊随访。通过比较两组干预前及干预12个月后，患者心功能指标、血浆中NT-pro BNP及预后评价的改变</p></sec><sec id="s6_4"><title>2.4. 观察指标</title><p>1) 两组患者治疗前后的血浆NT-pro BNP [<xref ref-type="bibr" rid="hanspub.37767-ref9">9</xref>]，正常值为0~300 pg/mL。</p><p>2) 左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)：LVEF正常值为50%~70%；LVESD男性正常值为25~37 mm，女性正常值为20~35 mm；LVEDD男性正常值为45~55 mm，女性正常值为 35~50 mm [<xref ref-type="bibr" rid="hanspub.37767-ref10">10</xref>]。</p><p>3) 预后评价：6分钟步行试验距离 [<xref ref-type="bibr" rid="hanspub.37767-ref11">11</xref>]，评价心功能状态；再住院率。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>两组数据采用SPSS 20.0统计学软件进行数据处理分析，计量资料采用( x &#175; &#177; s )表示，应用成对样本t检验，计数资料采用%表示，应用χ<sup>2</sup>检验，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者心功能指标比较：</title><p>两组患者干预治疗前的LVEF、LVEDD、LVESD的指标无明显差异(P &gt; 0.05)，干预治疗后，对照组和研究组的LVEF、LVEDD、LVESD指标较前均有所改善，且研究组的心功能指标均优于对照组，差异有统计学意义(P &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of cardiac function indexes between the two groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >左心室射血分数(%)</th><th align="center" valign="middle"  colspan="2"  >左心室舒张末内径(mm)</th><th align="center" valign="middle"  colspan="2"  >左心室收缩末内径(mm)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组(n = 107)</td><td align="center" valign="middle" >43.1 &#177; 4.3</td><td align="center" valign="middle" >46.4 &#177; 5.1</td><td align="center" valign="middle" >49.8 &#177; 5.2</td><td align="center" valign="middle" >46.3 &#177; 5.7</td><td align="center" valign="middle" >34.8 &#177; 4.1</td><td align="center" valign="middle" >32.5 &#177; 3.1</td></tr><tr><td align="center" valign="middle" >研究组(n = 107)</td><td align="center" valign="middle" >43.2 &#177; 5.8</td><td align="center" valign="middle" >51.0 &#177; 5.3</td><td align="center" valign="middle" >50.8 &#177; 6.7</td><td align="center" valign="middle" >42.9 &#177; 3.6</td><td align="center" valign="middle" >35.6 &#177; 4.9</td><td align="center" valign="middle" >30.9 &#177; 2.8</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >−0.187</td><td align="center" valign="middle" >−6.457</td><td align="center" valign="middle" >−1.233</td><td align="center" valign="middle" >5.178</td><td align="center" valign="middle" >−1.378</td><td align="center" valign="middle" >4.063</td></tr><tr><td align="center" valign="middle" >p值</td><td align="center" valign="middle" >0.852</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.219</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.170</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表1. 两组患者心功能指标比较( )</p></sec><sec id="s7_2"><title>3.2. 比较两组患者血浆NT-pro BNP水平</title><p>治疗前，两组患者血浆中NT-pro BNP无显著性差异(P &gt; 0.05)，经干预后，两组患者血浆中NT-pro BNP水平较前均有所下降，且研究组较对照组显著下降，差异有统计学意义(P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of NT-probNP between the two groups before and after treatment (pg/ml</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >NT-proBNP</th><th align="center" valign="middle"  rowspan="2"  >t值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组(n = 107)</td><td align="center" valign="middle" >2532.1 &#177; 1131.6</td><td align="center" valign="middle" >1322.4 &#177; 1211.7</td><td align="center" valign="middle" >7.323</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >研究组(n = 107)</td><td align="center" valign="middle" >2556.3 &#177; 966.8</td><td align="center" valign="middle" >473.4 &#177; 322</td><td align="center" valign="middle" >22.956</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >−0.169</td><td align="center" valign="middle" >7.004</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.866</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. 治疗前后两组NT-proBNP比较(pg/ml)</p></sec><sec id="s7_3"><title>3.3. 两组患者预后情况的比较</title><p>干预前，两组患者6 min步行距离比较无显著性差异(P &gt; 0.05)，经干预后，研究组患者6 min步行距离显著长于对照组，差异有统计学意义(P &lt; 0.05)。见表3。在随访1年内，两组患者无死亡发生，研究组再住院患者为12人，对照组再住院患者为18人，研究组再住院率低于对照组，但无显著差异(P &gt; 0.05)。见表3，表4。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of 6MWD between the two groups before and after treatment (m</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >6MWD</th><th align="center" valign="middle"  rowspan="2"  >t值</th><th align="center" valign="middle"  rowspan="2"  >p值</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >202.9 &#177; 42.4</td><td align="center" valign="middle" >252.3 &#177; 49.1</td><td align="center" valign="middle" >−8.384</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >197.5 &#177; 29.4</td><td align="center" valign="middle" >339.8 &#177; 52.4</td><td align="center" valign="middle" >−24.876</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >1.070</td><td align="center" valign="middle" >−12.620</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.286</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 治疗前后两组6MWD比较(m)</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of rehospitalization rate</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >再住院</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >18 (18)</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >12 (12)</td></tr><tr><td align="center" valign="middle" >χ<sup>2</sup>值</td><td align="center" valign="middle"  rowspan="2"  ></td><td align="center" valign="middle" >1.396</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.325</td></tr></tbody></table></table-wrap><p>表4. 再住院率比较[n(%)]</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>冠状动脉在多种因素 [<xref ref-type="bibr" rid="hanspub.37767-ref12">12</xref>] 的作用下引起管腔狭窄或闭塞导致心肌缺血缺氧或坏死，冠脉血流不能满足心肌代谢所需要的，就可引起心肌缺血缺氧，而持续的、严重的心肌缺血可引起心肌坏死即为心肌梗死 [<xref ref-type="bibr" rid="hanspub.37767-ref13">13</xref>]。心肌缺氧是需氧量增加和供氧减少两者共同作用的结果。心肌梗死可引起心肌重构，从而影响患者的心脏功能，尤为左心室的收缩功能的影响比较大，从而导致患者出现心力衰竭。对患者生命安全造成极大威胁，患者的死亡率会出现显著的升高。在心衰的治疗的过程中患者的预后影响因素是比较多的，出院后也要结合患者的实际情况和影响因素进行相应的综合治疗。</p><p>本研究过程中发现在网络平台的干预下，研究组患者的心功能及血浆NT-proBNP指标与对照组相比较，均有不同的改善，且研究组的心功能指标改善显著高于对照组差异具有有统计学意义(P &lt; 0.05)。提示干预治疗对心肌收缩力有改善作用。另外，人体血浆脑钠肽水平与心力衰竭的严重程度呈正相关，心力衰竭患者血浆中的NT-proBNP也是预测不良预后(包括死亡及住院)的独立因素，对于心衰患者而言，NT-proBNP处于长期稳定的水平，提示患者衰进展风险低，反之则预示心衰恶化，需要更密切的临床监测和随访 [<xref ref-type="bibr" rid="hanspub.37767-ref14">14</xref>]。比较两组患者，研究组的患者血浆NT-proBNP水平显著低于对照组，提示研究组的心衰进展风险低于对照组，降低了患者的再住院风险。相关研究表明，6 min步行距离同样与心力衰竭患者的预后存在相关性 [<xref ref-type="bibr" rid="hanspub.37767-ref15">15</xref>]。对于心力衰竭患者的预后，采用6 min步行距离也可进行预判，本研究结果显示，研究组能够显著增加患者的6 min步行距离，提高了患者的生活质量，证明在平台干预后，具有较好的改善患者预后的作用。</p><p>在既往的治疗过程中，缺乏有效的健康指导，不能根据出院患者自身因素进行有效的干预指导，通过健康网络管理平台，可以针对患者采取有效的预防手段，减少患者不良事件发生 [<xref ref-type="bibr" rid="hanspub.37767-ref16">16</xref>]。本研究在原常规治疗及随访的基础上通过采用网络平台进行相应干预，提醒及指导患者用药及心脏的康复指导，改善患者的生活治疗，降低患者再住院率。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究通过对心梗后心力衰竭患者的干预指导，心功能指标、血浆中NT-proBNP及6MWD得到有效改善，降低了患者再住院率，提高了患者的生活质量，改善了预后。</p></sec><sec id="s10"><title>声明</title><p>本研究已通过医院伦理委员会批准。</p></sec><sec id="s11"><title>文章引用</title><p>臧守亚,刘艳伟,张 驰,徐宝丽,苏 哲,管甲亮,李 喆,周长勇. 健康管理网络平台对心肌梗死后心力衰竭患者的干预研究Intervention Study of Health Management Network Platform in Patients with Heart Failure after Myocardial Infarction[J]. 临床医学进展, 2020, 10(09): 2102-2107. https://doi.org/10.12677/ACM.2020.109315</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37767-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">肖秋玉. 心肌梗死后心力衰竭的防治进展[J]. 心血管病防治知识(学术版), 2020, 10(3): 94-96.</mixed-citation></ref><ref id="hanspub.37767-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李路路, 张希玲, 王岩, 等. 不同性别急性心肌梗死合并心衰患者院内治疗及一年随访情况的比较[J]. 现代生物医学展, 2019(12): 2295-2298.</mixed-citation></ref><ref id="hanspub.37767-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">玉泽伟, 张华朝. 心肌梗死后心力衰竭防治现状及进展[J]. 中西医结合心血管病电子杂志, 2020, 8(10): 10-11</mixed-citation></ref><ref id="hanspub.37767-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">周平启, 吴 琼. 老年慢性心力衰竭的病因及临床治疗方式研究[J]. 临床医药文献电子杂志, 2016, 3(49): 9731.</mixed-citation></ref><ref id="hanspub.37767-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kulchitskaya, D.B., Shovkun, T.V., Yarnykh, E.V., et al. (2019) Impact of External Counterpulsation on Microcirculation in Patients with Coronary Heart Disease Complicated by Chronic Heart Failure after Surgical and Endovascular Myocardial Revascularization. Voprosy Kurortologii, Fizioterapii, Ilechebnoi Fizicheskoi Kultury, 96, 5-10. 
 &lt;br&gt;https://doi.org/10.17116/kurort2019960515</mixed-citation></ref><ref id="hanspub.37767-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tian, J., Yan, J.J., Zhang, Q., Yang, H., Chen, X., Han, Q., Han, R., Ren, J., Zhang, Y. and Han, Q. (2019) Analysis of re—Hospitalizations for Patients with Heart Failure Caused by Coronary Heart Disease: Data of First Event and Recur-Rent Event. Therapeutics and Clinical Risk Management, 15, 1333-1341.  
&lt;br&gt;https://doi.org/10.2147/TCRM.S218694</mixed-citation></ref><ref id="hanspub.37767-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李鹏磊. 多巴胺联合硝普钠治疗心梗后左心衰的临床探讨[J]. 疾病监测与控制, 2018, 12(4): 272-274.</mixed-citation></ref><ref id="hanspub.37767-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. (2018) Fourth Universal Definition of Myocardial Infarction. Circulation, 138, e618-e651. &lt;br&gt;https://doi.org/10.1161/CIR.0000000000000617</mixed-citation></ref><ref id="hanspub.37767-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.37767-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">韦沙. 阿托伐他汀治疗心肌梗死后无症状心衰患者的效果观察[J]. 现代医学与健康研究电子杂志, 2019, 3(6): 24-25.</mixed-citation></ref><ref id="hanspub.37767-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">张忠玲, 毛静远. 6分钟步行试验在慢性心力衰竭中的应用思考[J]. 吉林中医药, 2011, 31(7): 629-632.</mixed-citation></ref><ref id="hanspub.37767-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Valensi, P., Lorgis, L. and Cottin, Y. (2011) Prevalence, Incidence, Predictive Factors and Prognosis of Silent Myocardial Infarction: A Review of the Literature. Archives of Cardiovascular Diseases, 104, 178-188. 
&lt;br&gt;https://doi.org/10.1016/j.acvd.2010.11.013</mixed-citation></ref><ref id="hanspub.37767-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张新超, 于学忠, 陈凤英, 朱华栋. 急性冠脉综合征急诊快速诊治指南(2019) [J]. 临床急诊杂志, 2019, 20(4): 253-262.</mixed-citation></ref><ref id="hanspub.37767-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">亢扬, 富路. 心力衰竭患者血浆B型利钠肽/氨基末端利钠肽原水平正常的研究进展[J]. 心血管病学进展, 2018, 39(4): 622-626.</mixed-citation></ref><ref id="hanspub.37767-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">孔巴提∙沙提别克, 孟岩, 王红. 急性心肌梗死并发初诊心力衰竭住院患者的急性期生存率分析[J]. 中国医学前沿杂志(电子版), 2016, 8(1): 59-62.</mixed-citation></ref><ref id="hanspub.37767-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">米玛. 急性心肌梗死后心力衰竭的临床特点及预后分析[J]. 中西医结合心血管病电子杂志, 2020, 8(12): 76.</mixed-citation></ref></ref-list></back></article>